You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTerazosin
Accession NumberDB01162  (APRD00667)
TypeSmall Molecule
GroupsApproved
DescriptionTerazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.
Structure
Thumb
Synonyms
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine
Terazosin
Terazosina
Terazosine
Terazosinum
External Identifiers
  • Abbott 45975
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-terazosinTablet10 mgOralDominion Pharmacal2001-10-31Not applicableCanada
Dom-terazosinTablet1 mgOralDominion Pharmacal2001-10-31Not applicableCanada
Dom-terazosinTablet2 mgOralDominion Pharmacal2001-10-31Not applicableCanada
Dom-terazosinTablet5 mgOralDominion Pharmacal2001-10-31Not applicableCanada
HytrinTablet10 mgOralBgp Pharma Ulc1992-12-312016-02-19Canada
HytrinTablet1 mgOralBgp Pharma Ulc1989-12-312016-02-19Canada
HytrinTablet2 mgOralBgp Pharma Ulc1989-12-312016-02-19Canada
HytrinTablet5 mgOralBgp Pharma Ulc1989-12-31Not applicableCanada
Mylan-terazosinTablet10 mgOralMylan Pharmaceuticals Ulc2012-11-092016-06-28Canada
Mylan-terazosinTablet1 mgOralMylan Pharmaceuticals Ulc2012-11-092016-06-28Canada
Mylan-terazosinTablet2 mgOralMylan Pharmaceuticals Ulc2012-11-092016-06-28Canada
Mylan-terazosinTablet5 mgOralMylan Pharmaceuticals Ulc2012-11-092016-06-28Canada
Ntp-terazosinTablet5 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-terazosinTablet10 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-terazosinTablet1 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-terazosinTablet2 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-terazosinTablet5 mgOralNu Pharm Inc1998-03-052012-09-04Canada
Nu-terazosinTablet1 mgOralNu Pharm Inc1998-03-052012-09-04Canada
Nu-terazosinTablet2 mgOralNu Pharm Inc1998-03-052012-09-04Canada
Nu-terazosin 10 Mg TabletsTablet10 mgOralNu Pharm Inc1998-03-052012-09-04Canada
PHL-terazosinTablet10 mgOralPharmel Inc2004-08-04Not applicableCanada
PHL-terazosinTablet1 mgOralPharmel Inc2004-08-04Not applicableCanada
PHL-terazosinTablet2 mgOralPharmel Inc2004-08-04Not applicableCanada
PHL-terazosinTablet5 mgOralPharmel Inc2004-08-04Not applicableCanada
PMS-terazosinTablet10 mgOralPharmascience Inc2001-02-23Not applicableCanada
PMS-terazosinTablet1 mgOralPharmascience Inc2001-02-23Not applicableCanada
PMS-terazosinTablet2 mgOralPharmascience Inc2001-02-23Not applicableCanada
PMS-terazosinTablet5 mgOralPharmascience Inc2001-02-23Not applicableCanada
Ratio-terazosin - Tab 10mgTablet10 mgOralRatiopharm Inc Division Of Teva Canada Limited1997-10-312014-09-19Canada
Ratio-terazosin - Tab 1mgTablet1 mgOralRatiopharm Inc Division Of Teva Canada Limited1997-10-312014-09-19Canada
Ratio-terazosin - Tab 2mgTablet2 mgOralRatiopharm Inc Division Of Teva Canada Limited1997-10-312014-09-19Canada
Ratio-terazosin - Tab 5mgTablet5 mgOralRatiopharm Inc Division Of Teva Canada Limited1997-10-312014-09-19Canada
Riva-terazosin 1 Mg TabletsTablet1 mgOralLaboratoire Riva Inc1999-08-312003-07-28Canada
Riva-terazosin 10 Mg TabletsTablet10 mgOralLaboratoire Riva Inc1999-08-312003-07-28Canada
Riva-terazosin 2 Mg TabletsTablet2 mgOralLaboratoire Riva Inc1999-08-312003-07-28Canada
Riva-terazosin 5 Mg TabletsTablet5 mgOralLaboratoire Riva Inc1999-08-312003-07-28Canada
TerazosinTablet2 mgOralSanis Health Inc2010-05-12Not applicableCanada
TerazosinTablet5 mgOralSanis Health Inc2010-05-12Not applicableCanada
TerazosinTablet10 mgOralSanis Health Inc2010-05-12Not applicableCanada
TerazosinTablet1 mgOralSanis Health Inc2010-05-12Not applicableCanada
Terazosin-1Tablet1 mgOralPro Doc Limitee1998-06-02Not applicableCanada
Terazosin-10Tablet10 mgOralPro Doc Limitee1998-06-02Not applicableCanada
Terazosin-2Tablet2 mgOralPro Doc Limitee1998-06-02Not applicableCanada
Terazosin-5Tablet5 mgOralPro Doc Limitee1998-06-02Not applicableCanada
Teva-terazosinTablet1 mgOralTeva Canada Limited1998-02-09Not applicableCanada
Teva-terazosinTablet2 mgOralTeva Canada Limited1998-02-09Not applicableCanada
Teva-terazosinTablet5 mgOralTeva Canada Limited1998-02-09Not applicableCanada
Teva-terazosinTablet10 mgOralTeva Canada Limited1998-02-09Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-terazosinTablet1 mgOralApotex Inc1997-09-26Not applicableCanada
Apo-terazosinTablet2 mgOralApotex Inc1997-09-26Not applicableCanada
Apo-terazosinTablet5 mgOralApotex Inc1997-09-26Not applicableCanada
Apo-terazosinTablet10 mgOralApotex Inc1997-09-26Not applicableCanada
TarazosinCapsule5 mg/1OralMylan Institutional Inc.2000-04-01Not applicableUs
TarazosinCapsule1 mg/1OralMylan Institutional Inc.2000-04-01Not applicableUs
TarazosinCapsule2 mg/1OralMylan Institutional Inc.2000-04-01Not applicableUs
TerazosinCapsule10 mg/1OralA S Medication Solutions2001-04-12Not applicableUs
TerazosinCapsule1 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
TerazosinCapsule5 mg/1OralApotex Corp.2001-04-12Not applicableUs
TerazosinCapsule2 mg/1OralAidarex Pharmaceuticals LLC2001-04-12Not applicableUs
TerazosinCapsule5 mg/1OralJubilant Cadista Pharmaceuticals Inc.2004-12-20Not applicableUs
TerazosinCapsule5 mg/1OralA S Medication Solutions2004-12-20Not applicableUs
TerazosinCapsule10 mg/1OralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs
TerazosinCapsule2 mg/1OralNu Care Pharmaceuticals, Inc.2004-12-20Not applicableUs
TerazosinCapsule5 mg/1OralREMEDYREPACK INC.2013-09-19Not applicableUs
TerazosinCapsule10 mg/1OralApotex Corp.2001-04-12Not applicableUs
TerazosinCapsule2 mg/1OralREMEDYREPACK INC.2008-05-13Not applicableUs
TerazosinCapsule10 mg/1OralAidarex Pharmaceuticals LLC2001-04-12Not applicableUs
TerazosinCapsule2 mg/1OralNorthwind Pharmaceuticals, LLC2015-02-27Not applicableUs
TerazosinCapsule10 mg/1OralJubilant Cadista Pharmaceuticals Inc.2004-12-21Not applicableUs
TerazosinCapsule2 mg/1OralAidarex Pharmaceuticals LLC2004-12-20Not applicableUs
TerazosinCapsule2 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-03-30Not applicableUs
TerazosinCapsule10 mg/1OralREMEDYREPACK INC.2013-09-19Not applicableUs
TerazosinCapsule10 mg/1Oralbryant ranch prepack2004-12-21Not applicableUs
TerazosinCapsule1 mg/1OralJubilant Cadista Pharmaceuticals Inc.2004-12-20Not applicableUs
TerazosinCapsule1 mg/1OralA S Medication Solutions2004-12-20Not applicableUs
TerazosinCapsule5 mg/1OralProficient Rx LP2004-12-20Not applicableUs
TerazosinCapsule5 mg/1OralPreferred Pharmaceuticals, Inc.2013-07-12Not applicableUs
TerazosinCapsule10 mg/1OralA S Medication Solutions2004-12-21Not applicableUs
TerazosinCapsule5 mg/1OralNorthwind Pharmaceuticals, LLC2015-02-27Not applicableUs
TerazosinCapsule1 mg/1OralApotex Corp.2001-04-12Not applicableUs
TerazosinCapsule1 mg/1OralA S Medication Solutions2004-12-20Not applicableUs
TerazosinCapsule5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-03-03Not applicableUs
TerazosinCapsule1 mg/1OralREMEDYREPACK INC.2014-05-07Not applicableUs
TerazosinCapsule2 mg/1OralJubilant Cadista Pharmaceuticals Inc.2004-12-20Not applicableUs
TerazosinCapsule10 mg/1OralProficient Rx LP2004-12-21Not applicableUs
TerazosinCapsule1 mg/1OralAidarex Pharmaceuticals LLC2001-04-12Not applicableUs
TerazosinCapsule2 mg/1OralApotex Corp.2001-04-12Not applicableUs
TerazosinCapsule5 mg/1OralA S Medication Solutions2004-12-20Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1OralSandoz Inc1998-03-30Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralAphena Pharma Solutions Tennessee, Llc2004-12-20Not applicableUs
Terazosin HydrochlorideCapsule2 mg/1OralMajor Pharmaceuticals2009-11-02Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1OralREMEDYREPACK INC.2011-07-01Not applicableUs
Terazosin HydrochlorideCapsule2 mg/1OralUnit Dose Services1998-03-30Not applicableUs
Terazosin HydrochlorideCapsule2 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralREMEDYREPACK INC.2011-05-17Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-03-30Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1OralPhysicians Total Care, Inc.2003-06-02Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1Oralbryant ranch prepack2004-12-20Not applicableUs
Terazosin HydrochlorideCapsule2 mg/1OralPreferred Pharmaceuticals, Inc2012-04-05Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralMajor Pharmaceuticals2009-11-02Not applicableUs
Terazosin HydrochlorideCapsule2 mg/1OralREMEDYREPACK INC.2011-07-28Not applicableUs
Terazosin HydrochlorideCapsule2 mg/1OralSandoz Inc1998-03-30Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin HydrochlorideCapsule10 mg/1OralAphena Pharma Solutions Tennessee, Llc2004-12-21Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralA S Medication Solutions1998-03-30Not applicableUs
Terazosin HydrochlorideCapsule2 mg/1OralPhysicians Total Care, Inc.2000-09-05Not applicableUs
Terazosin HydrochlorideCapsule2 mg/1OralRebel Distributors Corp2009-07-01Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-07-01Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralCardinal Health2009-11-02Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1OralPreferred Pharmaceuticals, Inc2012-04-05Not applicableUs
Terazosin HydrochlorideCapsule2 mg/1OralREMEDYREPACK INC.2010-11-10Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1OralAphena Pharma Solutions Tennessee, Llc2004-12-20Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1OralREMEDYREPACK INC.2011-07-29Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralSandoz Inc1998-03-30Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralPhysicians Total Care, Inc.2000-08-29Not applicableUs
Terazosin HydrochlorideCapsule2 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-07-01Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralRebel Distributors Corp2009-07-01Not applicableUs
Terazosin HydrochlorideCapsule2 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1OralCardinal Health2009-11-02Not applicableUs
Terazosin HydrochlorideCapsule2 mg/1OralAphena Pharma Solutions Tennessee, Llc2004-12-20Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1OralMajor Pharmaceuticals2009-11-02Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralREMEDYREPACK INC.2011-06-09Not applicableUs
Terazosin HydrochlorideCapsule10 mg/1OralA S Medication Solutions1998-03-30Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralREMEDYREPACK INC.2011-08-16Not applicableUs
Terazosin HydrochlorideCapsule10 mg/1OralSandoz Inc1998-03-30Not applicableUs
Terazosin HydrochlorideCapsule2 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin HydrochlorideCapsule10 mg/1OralPhysicians Total Care, Inc.2000-08-29Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1Oralbryant ranch prepack2009-07-01Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralPreferred Pharmaceuticals, Inc2012-04-05Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralSTAT Rx USA LLC2004-12-20Not applicableUs
Terazosin HydrochlorideCapsule5 mg/1OralREMEDYREPACK INC.2011-11-09Not applicableUs
Terazosin HydrochlorideCapsule1 mg/1OralREMEDYREPACK INC.2013-05-132016-04-05Us
Terazosin HydrochlorideCapsule5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin Hydrochloride AnhydrousCapsule1 mg/1OralCardinal Health2011-01-28Not applicableUs
Terazosin Hydrochloride AnhydrousCapsule10 mg/1OralMylan Pharmaceuticals Inc.2000-02-22Not applicableUs
Terazosin Hydrochloride AnhydrousCapsule2 mg/1OralPd Rx Pharmaceuticals, Inc.2013-02-22Not applicableUs
Terazosin Hydrochloride AnhydrousCapsule5 mg/1OralCardinal Health2011-01-28Not applicableUs
Terazosin Hydrochloride AnhydrousCapsule1 mg/1OralMylan Pharmaceuticals Inc.2000-02-22Not applicableUs
Terazosin Hydrochloride AnhydrousCapsule2 mg/1OralMylan Pharmaceuticals Inc.2000-02-22Not applicableUs
Terazosin Hydrochloride AnhydrousCapsule5 mg/1OralMylan Pharmaceuticals Inc.2000-02-22Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BlavinBaliarda (Argentina)
FlumarcRaffo (Argentina)
FosfomicFinadiet (Argentina)
HeitrinAbbott (Germany; discontinued)
HytrinexAmdipharm (Sweden)
ItrinKeryos (Italy)
UrodieKeryos (Italy)
VicardAmdipharm (Austria)
ZayaselNot Available
Brand mixtures
NameLabellerIngredients
Hytrin-7 Tabs 1mg-7 Tabs 2mg-14 Tabs 5mgAbbott Laboratories, Limited
Salts
Name/CASStructureProperties
Terazosin Hydrochloride
63074-08-8
Thumb
  • InChI Key: IWSWDOUXSCRCKW-UHFFFAOYNA-N
  • Monoisotopic Mass: 423.167332052
  • Average Mass: 423.894
DBSALT000326
Categories
UNII8L5014XET7
CAS number63590-64-7
WeightAverage: 387.4329
Monoisotopic: 387.190654313
Chemical FormulaC19H25N5O4
InChI KeyVCKUSRYTPJJLNI-UHFFFAOYSA-N
InChI
InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
IUPAC Name
6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine
SMILES
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1
Pharmacology
IndicationFor the treatment of symptomatic BPH and mild to moderate hypertension.
Structured Indications
PharmacodynamicsTerazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an α-adrenergic blocking agent, terazosin is used to treat hypertension and BPH. Terazosin produces vasodilation and reduces peripheral resistance but in general has only a slight effect on cardiac output. The antihypertensive effect with chronic dosing is not usually accompanied by reflex tachycardia.
Mechanism of actionIn general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-Receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Terazosin is the first α1-receptor antagonist to demonstrate selectivity for the α1A-receptor. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of α1-receptors activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Terozosin produces its pharmacological effects by inhibiting α1A-receptor activation. Inhibition of these receptors in the vasculature and prostate results in muscle relaxation, decreased blood pressure and improved urinary outflow in symptomatic benign prostatic hyperplasia.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-1A adrenergic receptorProteinyes
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinyes
antagonist
HumanP35368 details
Alpha-1D adrenergic receptorProteinyes
antagonist
HumanP25100 details
Potassium voltage-gated channel subfamily H member 2Proteinunknown
inhibitor
HumanQ12809 details
Potassium voltage-gated channel subfamily H member 6Proteinunknown
inhibitor
HumanQ9H252 details
Potassium voltage-gated channel subfamily H member 7Proteinunknown
inhibitor
HumanQ9NS40 details
Related Articles
AbsorptionEssentially completely absorbed in man (90% bioavailability).
Volume of distributionNot Available
Protein binding90-94%
Metabolism

Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity.

Route of eliminationApproximately 10% of an orally administered dose is excreted as parent drug in the urine and approximately 20% is excreted in the feces.
Half life12 hours
ClearanceNot Available
ToxicityLD50=259.3mg/kg (IV in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Terazosin.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Terazosin.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Terazosin is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Terazosin.Approved, Vet Approved
AdrafinilTerazosin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Terazosin.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Terazosin.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Terazosin.Experimental
AlfuzosinAlfuzosin may increase the antihypertensive activities of Terazosin.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Terazosin is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Terazosin.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Terazosin.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Terazosin.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Terazosin is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Terazosin.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Terazosin is combined with Amiodarone.Approved, Investigational
AmitrazTerazosin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Terazosin.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Terazosin.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Terazosin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Terazosin is combined with Amphotericin B.Approved, Investigational
AmrinoneTerazosin may increase the hypotensive activities of Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Terazosin is combined with Amyl Nitrite.Approved
AnisodamineTerazosin may decrease the vasoconstricting activities of Anisodamine.Investigational
Aop200704Aop200704 may increase the orthostatic hypotensive activities of Terazosin.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Terazosin.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Terazosin is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Terazosin.Approved
ArbutamineTerazosin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolTerazosin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Terazosin.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Terazosin.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Terazosin.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Terazosin.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Terazosin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Terazosin.Approved, Investigational
AzelnidipineTerazosin may increase the hypotensive activities of Azelnidipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Terazosin is combined with Azilsartan medoxomil.Approved
AzimilideTerazosin may increase the hypotensive activities of Azimilide.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Terazosin.Experimental
BarbitalBarbital may increase the hypotensive activities of Terazosin.Illicit
BarnidipineTerazosin may increase the hypotensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Terazosin.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Terazosin.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Terazosin.Approved
BenidipineTerazosin may increase the hypotensive activities of Benidipine.Approved
BepridilTerazosin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Terazosin.Approved, Vet Approved
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Terazosin.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Terazosin.Approved
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Terazosin.Approved
BitolterolTerazosin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Terazosin.Approved
BopindololBopindolol may increase the orthostatic hypotensive activities of Terazosin.Approved
BortezomibThe risk or severity of adverse effects can be increased when Terazosin is combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Terazosin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Terazosin.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Terazosin.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Terazosin.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Terazosin.Approved, Investigational
BucindololTerazosin may increase the antihypertensive activities of Bucindolol.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Terazosin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Terazosin.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Terazosin is combined with Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Terazosin.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Terazosin.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Terazosin.Approved
CaiTerazosin may increase the hypotensive activities of Cai.Investigational
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Terazosin.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Terazosin is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Terazosin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Terazosin is combined with Captopril.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Terazosin.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Terazosin is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Terazosin.Approved
CarteololCarteolol may increase the orthostatic hypotensive activities of Terazosin.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Terazosin.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Terazosin.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Terazosin.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Terazosin.Withdrawn
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Terazosin.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Terazosin.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Terazosin.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Terazosin is combined with Cilazapril.Approved
CilnidipineTerazosin may increase the hypotensive activities of Cilnidipine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Terazosin.Approved
CinnarizineTerazosin may increase the hypotensive activities of Cinnarizine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Terazosin.Approved, Investigational
CirazolineTerazosin may decrease the vasoconstricting activities of Cirazoline.Experimental
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Terazosin.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Terazosin.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Terazosin.Approved
ClenbuterolTerazosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Terazosin is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Terazosin.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Terazosin is combined with Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Terazosin.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Terazosin is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Terazosin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Terazosin.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Terazosin.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Terazosin.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Terazosin.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Terazosin is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Terazosin.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Terazosin.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Terazosin.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Terazosin.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Terazosin.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Terazosin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Terazosin is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Terazosin.Investigational
DarodipineTerazosin may increase the hypotensive activities of Darodipine.Experimental
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Terazosin.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Terazosin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Terazosin.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Terazosin is combined with Desflurane.Approved
DetomidineTerazosin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Terazosin.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Terazosin.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Terazosin.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Terazosin.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Terazosin.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Terazosin.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Terazosin.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Terazosin.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Terazosin.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Terazosin is combined with Dinutuximab.Approved
DipivefrinTerazosin may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Terazosin.Approved
DobutamineTerazosin may decrease the vasoconstricting activities of Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Terazosin.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Terazosin.Approved, Investigational, Vet Approved
DotarizineTerazosin may increase the hypotensive activities of Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Terazosin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Terazosin.Approved, Investigational
DroxidopaTerazosin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineTerazosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Terazosin.Approved
EfonidipineTerazosin may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Terazosin.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Terazosin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Terazosin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Terazosin is combined with Enalaprilat.Approved
EperisoneTerazosin may increase the hypotensive activities of Eperisone.Approved, Investigational
EphedrineTerazosin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Terazosin.Approved, Investigational
EpinephrineTerazosin may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Terazosin.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Terazosin is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Terazosin.Approved
ErgotamineTerazosin may decrease the vasoconstricting activities of Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Terazosin.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Terazosin.Approved, Vet Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Terazosin.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Terazosin.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Terazosin.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Terazosin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Terazosin.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Terazosin.Approved
EtilefrineTerazosin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Terazosin.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Terazosin.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Terazosin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Terazosin.Approved, Investigational
FendilineTerazosin may increase the hypotensive activities of Fendiline.Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Terazosin is combined with Fenoldopam.Approved
FenoterolTerazosin may decrease the vasoconstricting activities of Fenoterol.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Terazosin.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Terazosin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Terazosin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Terazosin is combined with Fimasartan.Approved
FlunarizineTerazosin may increase the hypotensive activities of Flunarizine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Terazosin.Approved
FormoterolTerazosin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Terazosin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Terazosin.Approved, Vet Approved
GabapentinTerazosin may increase the hypotensive activities of Gabapentin.Approved, Investigational
GallopamilTerazosin may increase the hypotensive activities of Gallopamil.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Terazosin.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Terazosin.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Terazosin.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Terazosin.Withdrawn
GuanabenzTerazosin may decrease the vasoconstricting activities of Guanabenz.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Terazosin.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Terazosin.Approved
HalothaneThe risk or severity of adverse effects can be increased when Terazosin is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Terazosin.Approved
HexoprenalineTerazosin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineTerazosin may decrease the vasoconstricting activities of Higenamine.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Terazosin is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Terazosin.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Terazosin.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Terazosin is combined with Hydroflumethiazide.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Terazosin.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Terazosin.Approved
IloprostThe risk or severity of adverse effects can be increased when Terazosin is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Terazosin.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Terazosin is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Terazosin.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Terazosin.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Terazosin.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Terazosin.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Terazosin.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Terazosin.Approved, Investigational
IndoraminTerazosin may increase the antihypertensive activities of Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Terazosin.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Terazosin.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Terazosin is combined with Isocarboxazid.Approved
IsoetarineTerazosin may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Terazosin is combined with Isoflurane.Approved, Vet Approved
IsoprenalineTerazosin may decrease the vasoconstricting activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Terazosin.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Terazosin.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Terazosin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Terazosin.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Terazosin.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Terazosin.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Terazosin.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Terazosin.Approved
LacidipineTerazosin may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Terazosin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Terazosin.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Terazosin.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Terazosin.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Terazosin.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Terazosin.Approved
LercanidipineTerazosin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Terazosin.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Terazosin is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Terazosin is combined with Levobupivacaine.Approved
LevodopaTerazosin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Terazosin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Terazosin.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Terazosin is combined with Levosimendan.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Terazosin.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Terazosin.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Terazosin is combined with Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Terazosin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Terazosin.Approved
Magnesium SulfateTerazosin may increase the hypotensive activities of Magnesium Sulfate.Approved, Vet Approved
ManidipineTerazosin may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Terazosin.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Terazosin.Approved
MedetomidineTerazosin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MephentermineTerazosin may decrease the vasoconstricting activities of Mephentermine.Approved
MetaraminolTerazosin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Terazosin.Approved
MethohexitalMethohexital may increase the hypotensive activities of Terazosin.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Terazosin.Approved
MethoxamineTerazosin may decrease the vasoconstricting activities of Methoxamine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Terazosin.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Terazosin.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Terazosin.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Terazosin.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Terazosin is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Terazosin.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Terazosin.Approved, Investigational
MibefradilTerazosin may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Terazosin.Approved, Illicit
MidodrineTerazosin may decrease the vasoconstricting activities of Midodrine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Terazosin.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Terazosin.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Terazosin.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Terazosin.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Terazosin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Terazosin is combined with Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Terazosin.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Terazosin is combined with Nabilone.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Terazosin.Approved
NaftopidilTerazosin may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Terazosin.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Terazosin.Approved, Vet Approved
NaphazolineTerazosin may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololThe risk or severity of adverse effects can be increased when Terazosin is combined with Nebivolol.Approved, Investigational
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Terazosin.Approved
NesiritideThe risk or severity of adverse effects can be increased when Terazosin is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Terazosin.Approved
NicorandilNicorandil may increase the hypotensive activities of Terazosin.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Terazosin.Approved
NiguldipineTerazosin may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Terazosin.Approved, Investigational
NiludipineTerazosin may increase the hypotensive activities of Niludipine.Experimental
NilvadipineTerazosin may increase the hypotensive activities of Nilvadipine.Approved
NimesulideTerazosin may increase the hypotensive activities of Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Terazosin.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Terazosin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Terazosin.Approved
NitrendipineTerazosin may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Terazosin is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Terazosin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Terazosin.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Terazosin.Approved
NorepinephrineTerazosin may decrease the vasoconstricting activities of Norepinephrine.Approved
NylidrinTerazosin may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Terazosin is combined with Obinutuzumab.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Terazosin.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Terazosin.Approved, Investigational
OlodaterolTerazosin may decrease the vasoconstricting activities of Olodaterol.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Terazosin.Approved
OrciprenalineTerazosin may decrease the vasoconstricting activities of Orciprenaline.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Terazosin.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Terazosin.Approved
OxymetazolineTerazosin may decrease the vasoconstricting activities of Oxymetazoline.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Terazosin.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Terazosin.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Terazosin.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Terazosin.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Terazosin.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Terazosin.Approved, Vet Approved
PerhexilineTerazosin may increase the hypotensive activities of Perhexiline.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Terazosin.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Terazosin is combined with Phenelzine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Terazosin.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Terazosin is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Terazosin is combined with Phentolamine.Approved
PhenylephrineTerazosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineTerazosin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Terazosin.Approved, Vet Approved
PinaveriumTerazosin may increase the hypotensive activities of Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Terazosin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Terazosin is combined with Pipamperone.Approved
PirbuterolTerazosin may decrease the vasoconstricting activities of Pirbuterol.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Terazosin.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Terazosin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Terazosin.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Terazosin.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Terazosin is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Terazosin.Approved
PrazosinPrazosin may increase the antihypertensive activities of Terazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Terazosin.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Terazosin.Approved, Vet Approved
PregabalinTerazosin may increase the hypotensive activities of Pregabalin.Approved, Illicit, Investigational
PrenylamineTerazosin may increase the hypotensive activities of Prenylamine.Withdrawn
PrimidonePrimidone may increase the hypotensive activities of Terazosin.Approved, Vet Approved
ProcaterolTerazosin may decrease the vasoconstricting activities of Procaterol.Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Terazosin.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Terazosin is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Terazosin.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Terazosin.Approved
PseudoephedrineTerazosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Terazosin is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Terazosin.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Terazosin.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Terazosin.Approved
RacepinephrineTerazosin may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopamineTerazosin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Terazosin.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Terazosin.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Terazosin.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Terazosin is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Terazosin is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Terazosin.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Terazosin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Terazosin.Approved, Investigational
RilmenidineTerazosin may decrease the vasoconstricting activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Terazosin is combined with Riociguat.Approved
RisedronateTerazosin may increase the hypotensive activities of Risedronate.Approved, Investigational
RisperidoneTerazosin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronTerazosin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineTerazosin may decrease the vasoconstricting activities of Ritodrine.Approved
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Terazosin.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Terazosin.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Terazosin.Approved, Investigational
RomifidineTerazosin may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe risk or severity of adverse effects can be increased when Terazosin is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Terazosin is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Terazosin is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Terazosin is combined with Sacubitril.Approved
SalbutamolTerazosin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Terazosin.Approved, Vet Approved
SalmeterolTerazosin may decrease the vasoconstricting activities of Salmeterol.Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Terazosin.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Terazosin.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Terazosin is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Terazosin.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Terazosin is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Terazosin.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Terazosin.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Terazosin.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Terazosin.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Terazosin is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Terazosin.Approved
SolabegronTerazosin may decrease the vasoconstricting activities of Solabegron.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Terazosin.Approved, Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Terazosin.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Terazosin.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Terazosin.Experimental
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Terazosin.Approved
SR 58611Terazosin may decrease the vasoconstricting activities of SR 58611.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Terazosin is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Terazosin is combined with Sufentanil.Approved, Investigational
SynephrineTerazosin may decrease the vasoconstricting activities of Synephrine.Experimental
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Terazosin.Approved, Investigational
TadalafilTadalafil may increase the hypotensive activities of Terazosin.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Terazosin.Approved
TamsulosinTamsulosin may increase the antihypertensive activities of Terazosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Terazosin.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Terazosin.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Terazosin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Terazosin.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Terazosin.Approved
TerbutalineTerazosin may decrease the vasoconstricting activities of Terbutaline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Terazosin is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Terazosin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Terazosin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Terazosin is combined with Thioridazine.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Terazosin.Approved
TimololTimolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Terazosin.Approved
TolazolineThe risk or severity of adverse effects can be increased when Terazosin is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Terazosin is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTerazosin may increase the hypotensive activities of Tolfenamic Acid.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Terazosin.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Terazosin.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Terazosin.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Terazosin.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Terazosin.Approved
TranilastTerazosin may increase the hypotensive activities of Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Terazosin is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Terazosin.Approved
TretinoinThe risk or severity of adverse effects can be increased when Terazosin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Terazosin.Approved
TrimazosinTerazosin may increase the antihypertensive activities of Trimazosin.Experimental
TulobuterolTerazosin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Terazosin.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Terazosin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Terazosin.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Terazosin.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Terazosin.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Terazosin.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Terazosin.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Terazosin.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Terazosin.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Terazosin.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Terazosin.Approved, Investigational
VinpocetineTerazosin may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Terazosin.Approved
XylazineTerazosin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineTerazosin may increase the hypotensive activities of Xylometazoline.Approved
YM-178Terazosin may decrease the vasoconstricting activities of YM-178.Investigational
ZiconotideTerazosin may increase the hypotensive activities of Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Terazosin.Approved
Food InteractionsNot Available
References
Synthesis Reference

K. S. Keshava Murthy, Gamini Weeratunga, Tianhao Zhou, Bhaskar Reddy Guntoori, “Process for the manufacture of intermediates suitable to make doxazosin, terazosin, prazosin, tiodazosin and related antihypertensive medicines.” U.S. Patent US5919931, issued September, 1986.

US5919931
General References
  1. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [PubMed:12461301 ]
External Links
ATC CodesG04CA03
AHFS Codes
  • 24:20.00
PDB EntriesNot Available
FDA labelDownload (1020 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9646
Caco-2 permeable+0.8868
P-glycoprotein substrateSubstrate0.698
P-glycoprotein inhibitor INon-inhibitor0.5666
P-glycoprotein inhibitor IINon-inhibitor0.8619
Renal organic cation transporterNon-inhibitor0.6319
CYP450 2C9 substrateNon-substrate0.8864
CYP450 2D6 substrateNon-substrate0.8032
CYP450 3A4 substrateSubstrate0.7753
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9435
CYP450 2D6 inhibitorNon-inhibitor0.9628
CYP450 2C19 inhibitorNon-inhibitor0.9492
CYP450 3A4 inhibitorNon-inhibitor0.7905
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.901
Ames testNon AMES toxic0.5943
CarcinogenicityNon-carcinogens0.906
BiodegradationNot ready biodegradable0.9785
Rat acute toxicity2.2262 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8368
hERG inhibition (predictor II)Inhibitor0.8204
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Kit; tabletOral
CapsuleOral1 mg/1
CapsuleOral10 mg/1
CapsuleOral2 mg/1
CapsuleOral5 mg/1
TabletOral1 mg
TabletOral10 mg
TabletOral2 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Hytrin 10 mg Tablet1.85USD tablet
Terazosin HCl 1 mg capsule1.67USD capsule
Terazosin HCl 10 mg capsule1.67USD capsule
Terazosin HCl 2 mg capsule1.67USD capsule
Terazosin HCl 5 mg capsule1.67USD capsule
Hytrin 5 mg Tablet1.26USD tablet
Hytrin 2 mg Tablet0.93USD tablet
Apo-Terazosin 10 mg Tablet0.92USD tablet
Novo-Terazosin 10 mg Tablet0.92USD tablet
Nu-Terazosin 10 mg Tablet0.92USD tablet
Pms-Terazosin 10 mg Tablet0.92USD tablet
Ratio-Terazosin 10 mg Tablet0.92USD tablet
Hytrin 1 mg Tablet0.73USD tablet
Apo-Terazosin 5 mg Tablet0.63USD tablet
Novo-Terazosin 5 mg Tablet0.63USD tablet
Nu-Terazosin 5 mg Tablet0.63USD tablet
Pms-Terazosin 5 mg Tablet0.63USD tablet
Ratio-Terazosin 5 mg Tablet0.63USD tablet
Apo-Terazosin 2 mg Tablet0.46USD tablet
Novo-Terazosin 2 mg Tablet0.46USD tablet
Nu-Terazosin 2 mg Tablet0.46USD tablet
Pms-Terazosin 2 mg Tablet0.46USD tablet
Ratio-Terazosin 2 mg Tablet0.46USD tablet
Apo-Terazosin 1 mg Tablet0.37USD tablet
Novo-Terazosin 1 mg Tablet0.37USD tablet
Nu-Terazosin 1 mg Tablet0.37USD tablet
Pms-Terazosin 1 mg Tablet0.37USD tablet
Ratio-Terazosin 1 mg Tablet0.37USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5212176 No1993-06-292010-06-29Us
US5294615 No1993-04-292013-04-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point273 °CPhysProp
water solubility29.7mg/mLNot Available
logP1Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.5 mg/mLALOGPS
logP1.12ALOGPS
logP1.18ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)19.93ChemAxon
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area103.04 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity105.18 m3·mol-1ChemAxon
Polarizability41.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Quinazolinamine
  • Quinazoline
  • Dialkylarylamine
  • Anisole
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Primary aromatic amine
  • Saccharide
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Oxolane
  • Tertiary amine
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Chapple CR: Medical therapy and quality of life. Eur Urol. 1998;34 Suppl 2:10-7; discussion 46. [PubMed:9732824 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Lee E, Lee C: Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997 Oct;80(4):606-11. [PubMed:9352700 ]
  4. Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D: Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8. [PubMed:8736427 ]
  5. Na YJ, Guo YL, Gu FL: Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med. 1998;29(5-6):289-304. [PubMed:10503165 ]
  6. Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35. [PubMed:14767264 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG: Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology. 2001 Nov;58(5):717-22. [PubMed:11711348 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Simpson P: Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ Res. 1985 Jun;56(6):884-94. [PubMed:2988814 ]
  4. Vincent J, Dachman W, Blaschke TF, Hoffman BB: Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90(5):1763-8. [PubMed:1358918 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:
KCNH6
Uniprot ID:
Q9H252
Molecular Weight:
109923.705 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:
KCNH7
Uniprot ID:
Q9NS40
Molecular Weight:
134998.525 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11